# Primary Membranous Nephropathy FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/primary-membranous-nephropathy

> 12 upcoming FDA catalysts in primary Membranous Nephropathy: ALXN1920 (AZN) on Jul to Oct 2027 (topline data readout); ALXN1920 (AZN) on July 2027 (primary completion); BRUKINSA® (zanubrutinib, ONC) on October 2027 (primary completion); BRUKINSA® (zanubrutinib, ONC) on Oct 2027 to Jan 2028 (topline data readout); and 8 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jul to Oct 2027 | [ALXN1920 topline data readout](https://sec-api.dev/pdufa/alxn1920) | AZN | Primary Membranous Nephropathy | scheduled | "NCT07157787 (Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-02 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07157787)) |
| July 2027 | [ALXN1920 primary completion](https://sec-api.dev/pdufa/alxn1920) | AZN | Primary Membranous Nephropathy | scheduled | "NCT07157787 (Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-02 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07157787)) |
| October 2027 | [BRUKINSA® (zanubrutinib) primary completion](https://sec-api.dev/pdufa/zanubrutinib) | ONC | Primary Membranous Nephropathy | scheduled | "NCT05707377 (A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05707377)) |
| Oct 2027 to Jan 2028 | [BRUKINSA® (zanubrutinib) topline data readout](https://sec-api.dev/pdufa/zanubrutinib) | ONC | Primary Membranous Nephropathy | scheduled | "NCT05707377 (A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05707377)) |
| October 2027 | [Budoprutug primary completion](https://sec-api.dev/pdufa/budoprutug) | CLYM | Primary Membranous Nephropathy | scheduled | "NCT07096843 (A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Climb Bio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07096843)) |
| Oct 2027 to Jan 2028 | [Budoprutug topline data readout](https://sec-api.dev/pdufa/budoprutug) | CLYM | Primary Membranous Nephropathy | scheduled | "NCT07096843 (A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Climb Bio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07096843)) |
| Oct 2028 to Jan 2029 | [Surovatamig topline data readout](https://sec-api.dev/pdufa/surovatamig) | AZN | Primary Membranous Nephropathy | scheduled | "NCT07571746 (A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-10-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07571746)) |
| October 2028 | [Surovatamig primary completion](https://sec-api.dev/pdufa/surovatamig) | AZN | Primary Membranous Nephropathy | scheduled | "NCT07571746 (A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-10-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07571746)) |
| Dec 2028 to Mar 2029 | [Povetacicept topline data readout](https://sec-api.dev/pdufa/povetacicept) | VRTX | Primary Membranous Nephropathy | scheduled | "NCT07204275 (Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-12-29 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07204275)) |
| December 2028 | [Povetacicept primary completion](https://sec-api.dev/pdufa/povetacicept) | VRTX | Primary Membranous Nephropathy | scheduled | "NCT07204275 (Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-12-29 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07204275)) |
| Jan to Apr 2030 | [Felzartamab topline data readout](https://sec-api.dev/pdufa/felzartamab) | BIIB | Primary Membranous Nephropathy | scheduled | "NCT06962800 (A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-28 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06962800)) |
| January 2030 | [Felzartamab primary completion](https://sec-api.dev/pdufa/felzartamab) | BIIB | Primary Membranous Nephropathy | scheduled | "NCT06962800 (A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-28 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06962800)) |

## Drugs

- [ALXN1920](https://sec-api.dev/pdufa/alxn1920) (AZN)
- [BRUKINSA® (zanubrutinib)](https://sec-api.dev/pdufa/zanubrutinib) (ONC)
- [Budoprutug](https://sec-api.dev/pdufa/budoprutug) (CLYM)
- [Surovatamig](https://sec-api.dev/pdufa/surovatamig) (AZN)
- [Povetacicept](https://sec-api.dev/pdufa/povetacicept) (VRTX)
- [Felzartamab](https://sec-api.dev/pdufa/felzartamab) (BIIB)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/primary-membranous-nephropathy.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Primary Membranous Nephropathy FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/primary-membranous-nephropathy

```bibtex
@misc{secapidev_indications_primary_membranous_nephropathy_20261116,
  title        = {Primary Membranous Nephropathy FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/primary-membranous-nephropathy}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_primary_membranous_nephropathy_20261116","title":"Primary Membranous Nephropathy FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/primary-membranous-nephropathy","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
